Abstract:ABSTRACT Previous studies have shown that the gut microbiota and its metabolites are associated with the success of organ transplantation. However, the specific changes in the gut microbiota of lung transplant patients remain unclear. Hence, this study aimed to elucidate the interplay between the gut microbiota, metabolome, and lung transplantation outcomes. Using 16S metagenomics sequencing and untargeted metabolic profiling, we conducted a comprehensive analysis of gut microbial and metabolic alterations in lung transplant recipients relative to non-transplant group. Our findings revealed the predominance of Enterococcus and Streptococcus genera within the lung transplant cohort, accompanied by the significant reduction in Bacteroides , Epulopiscium , Faecalibacterium , and Prevotella abundance. In addition, a significant reduction in ATRA (all-trans retinoic acid) levels and suppression of IgA production were observed in lung transplant recipients, which were found to be closely associated with the Enterococcus genus. It was speculated that the association might have implications for the prognosis of lung transplant patients. Notably, the differences in gut microbial composition and metabolomic profiles between successful transplant recipients and those experiencing chronic rejection were not statistically significant. These novel insights shed light on the putative implications of the gut microbiota and metabolome in shaping lung transplantation outcomes, and provide a foundation for future investigations and targeted therapeutic interventions. IMPORTANCE This study has profound implications for lung transplantation as it uncovers the important role of gut microbiota and metabolome in shaping transplantation outcomes. The identification of dominant bacterial genera, such as Enterococcus and Streptococcus , within the lung transplant cohort, along with the significant decrease in Bacteroides , Epulopiscium , Faecalibacterium , and Prevotella abundance, reveals potential microbial imbalances associated with lung transplantation. In addition, a significant reduction in ATRA (all-trans retinoic acid) levels and suppression of IgA production were observed in lung transplant recipients, which were found to be closely associated with the Enterococcus genus. It was speculated that the association might have implications for the prognosis of lung transplant patients. These findings hold immense clinical significance as they lay the groundwork for future research and targeted therapeutic interventions. Understanding the impact of the gut microbiota and metabolome on lung transplantation outcomes offers promising avenues for improving transplantation patient prognosis.

Microbiome and metabolome patterns after lung transplantation reflect underlying disease and chronic lung allograft dysfunction

Unique Changes in the Lung Microbiome following the Development of Chronic Lung Allograft Dysfunction

The Lung Microbiome Predicts Mortality and Response to Azithromycin in Lung Transplant Patients with Chronic Rejection

Navigating Immune Cell Immunometabolism after Liver Transplantation

Spectrum of chronic lung allograft dysfunction pathology in human lung transplantation

Multi-omics profiling predicts allograft function after lung transplantation

Understanding the Impact of Macrophages on Lung Transplant Outcomes

Systems prediction of chronic lung allograft dysfunction: Results and perspectives from the Cohort of Lung Transplantation and Systems prediction of Chronic Lung Allograft Dysfunction cohorts

Impaired complement regulation drives chronic lung allograft dysfunction after lung transplantation.

High-dimensional tissue profiling of immune cell responses in chronic lung allograft dysfunction

Beyond the organ: lung microbiome shapes transplant indications and outcomes

Lung transplantation in adults and children: putting lung function into perspective

The gut microbiome in end-stage lung disease and lung transplantation

Single-cell multi-omic analysis of post-transplant mesenchymal cells reveals molecular signatures and putative regulators of lung fibrosis

LTB4 and Montelukast in Transplantation-Related Bronchiolitis Obliterans in Rats

Insights from T Cell Profiling in BAL and PBMC

Microbiosis in Lung Allotransplantation and Xenotransplantation: State of the Art and Future Perspective

Lung Allograft Microbiome Association with Gastroesophageal Reflux, Inflammation, and Allograft Dysfunction

Longitudinal Lower Airway Microbial Signatures of Acute Cellular Rejection in Lung Transplantation

Analysis on the change of gut microbiota and metabolome in lung transplant patients

Validation and Refinement of Chronic Lung Allograft Dysfunction Phenotypes in Bilateral and Single Lung Recipients